SHERIDAN, WYOMING - March 04, 2026 - Teva has secured $400 million in funding from Blackstone Life Sciences to advance duvakitug, a Sanofi-partnered TL1A blocker in development for inflammatory bowel diseases. The financing is structured to be disbursed over four years and includes regulatory and undisclosed commercial milestones, plus low single-digit royalties on worldwide sales. For Teva, the deal adds non-dilutive-style runway and a clearer capital path for a program that already has defined Phase 3 responsibilities with Sanofi. For operators, it underscores how external capital is increasingly being used to sustain late-stage clinical programs while preserving strategic partnerships and commercialization options.
Deal structure and what it changes for program funding
Teva said Blackstone will provide $400 million across four years, with eligibility for regulatory milestones and undisclosed commercial milestones tied to duvakitug. Blackstone will also be entitled to low single-digit royalties on worldwide sales.
From a program management standpoint, the structure matters because it spreads funding over time and links additional economics to execution gates, which can reduce near-term balance sheet pressure while keeping incentives aligned around development progress and commercialization outcomes.
Asset profile and clinical signal highlighted in recent data
Duvakitug is described as a monoclonal antibody that blocks the TL1A cytokine, dampening the inflammatory response while also reducing fibrosis. Teva pointed to Phase 2b data from the RELIEVE UCCD LTE study, describing durability of benefit across induction and maintenance treatment. After 14 weeks of induction treatment and 44 weeks of maintenance with 900-mg duvakitug, 58% of patients with ulcerative colitis and and 55% of patients with Crohn's disease remained in clinical remission.
Operationally, this kind of durability framing is often used to support Phase 3 investment decisions, particularly when sponsors must justify multi-year trial execution, site burden, and manufacturing scale-up planning.
Sanofi partnership mechanics and late-stage handoff
The source states that Sanofi invested $500 million upfront in October 2023 to gain co-development and co-commercialization rights over duvakitug, with up to $1 billion in development and launch milestones also promised. As part of that 2023 contract, Sanofi will take charge of duvakitug's clinical development once it reaches Phase 3.
Sanofi has since launched the late-stage STARSCAPE-1 study in Crohn's disease and SUNSCAPE-1 trial in ulcerative colitis. The former is expected to complete in 2029 while the latter will wrap up in 2028. For delivery teams, that division of responsibilities clarifies who will drive late-stage operational execution, which typically influences vendor strategy, trial governance, and resourcing plans.
What private equity participation can mean for governance and incentives
The transaction is framed as part of a broader pattern of private equity participation in biopharma funding, especially as market conditions push companies to seek available capital. For operating leaders, the practical questions are less about the headline amount and more about how new stakeholders influence decision cadence, risk tolerance, and prioritization across a portfolio.
In this case, the economic participation described is tied to milestones and royalties rather than operational control, which can preserve day-to-day development decision-making while still embedding performance-linked obligations into the program's long-term economics.
"PE-ization of pharma"
Execution focus areas that typically follow milestone-and-royalty financings
Based on the deal terms and the disclosed development plan, teams typically concentrate on predictability and documentation quality across the functions that drive milestone attainment and downstream royalties. In practical terms, that often includes:
- Clinical operations discipline to keep late-stage timelines and site performance stable
- CMC readiness to ensure manufacturing and quality systems can support Phase 3 and beyond
- Regulatory execution planning to avoid avoidable rework as programs transition into pivotal stages
- Cross-partner governance to keep Teva and Sanofi aligned on program decisions as Phase 3 responsibilities shift
This is not unique to duvakitug, but the multi-party economics heighten the value of clean interfaces between sponsor responsibilities, evidence packages, and decision rights.
Market context: why these structures are showing up more often
The source frames the financing against "unforgiving market conditions" that have left biopharma companies eager for funding, creating opportunities for private equity to invest and potentially benefit if assets reach market or are sold. This dynamic is described as a shift from historic private equity caution due to the binary risk profile of drug development.
"A lot of these folks are seeing opportunity now in biotech and distressed assets, and it's hard to pass off," Helal told BioSpace.